Epigral Ltd (IN:EPIGRAL)
:EPIGRAL
Want to see IN:EPIGRAL full AI Analyst Report?
EPIGRAL Stock Chart & Stats
₹1244.30
-₹4.30(-0.24%)
At close: 4:00 PM EST
₹1244.30
-₹4.30(-0.24%)
Day’s Range― - ―
52-Week Range₹806.20 - ₹2,114.30
Previous CloseN/A
Volume42.70K
Average Volume (3M)1.86K
Market Cap
₹53.59B
Enterprise Value₹59.18B
Total Cash (Recent Filing)₹485.70M
Total Debt (Recent Filing)₹5.37B
Price to Earnings (P/E)10.8
Beta1.55
Next Earnings
Aug 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.46%
Share Statistics
EPS (TTM)93.51
Shares Outstanding43,141,340
10 Day Avg. Volume1,295
30 Day Avg. Volume1,859
Financial Highlights & Ratios
PEG Ratio-1.15
Price to Book (P/B)1.57
Price to Sales (P/S)1.38
P/FCF Ratio-535.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)72.45
Revenue Forecast (FY)₹30.13B
Bulls Say, Bears Say
Bulls Say
Strengthened Balance SheetLeverage has been cut materially to about 0.26x equity and equity has expanded, lowering financial risk. A stronger balance sheet improves resilience through industry cycles, sustains investment capacity for maintenance/capex, and preserves strategic optionality over the next 2–6 months.
Vertical Integration And Product MixIntegrated chlor-alkali production plus downstream derivatives reduces disposal cost risk and captures more value per unit of feedstock. This diversification across bulk and value-added chemicals stabilizes realizations, supports margins, and creates structural competitive advantages versus pure commodity producers.
Solid Operating ProfitabilityReported operating and net margins remain robust for the chemical sector, indicating structural earnings strength. Sustained mid-teens margins support internal funding for maintenance and selective expansion, and provide a cushion against raw-material cost swings over a multi-month horizon.
Bears Say
Weak Cash GenerationFree cash flow deterioration and low cash conversion reduce internal funding for growth or debt reduction, increasing reliance on external financing. Persistent weak FCF can constrain capital allocation, impair flexibility for cyclical downturns, and raise refinancing risk over the coming quarters.
Revenue Volatility / Weak Recent GrowthRevenue stagnation and historical volatility signal sensitivity to end-market demand and pricing swings. Without consistent top-line expansion, margin leverage is limited and investment recoveries become harder, increasing operational risk and making multi-quarter planning more uncertain.
Margin Compression And Softer Earnings PowerMaterial compression in gross and operating margins weakens the firm's ability to absorb input-cost shocks. Softer earnings reduce retained earnings available for reinvestment or debt paydown, and indicate exposure to adverse spreads in chlor-alkali feedstock and product markets over the next several quarters.
Epigral Ltd News
EPIGRAL FAQ
What was Epigral Ltd’s price range in the past 12 months?
Epigral Ltd lowest stock price was ₹806.20 and its highest was ₹2114.30 in the past 12 months.
What is Epigral Ltd’s market cap?
Epigral Ltd’s market cap is ₹53.59B.
When is Epigral Ltd’s upcoming earnings report date?
Epigral Ltd’s upcoming earnings report date is Aug 03, 2026 which is in 74 days.
How were Epigral Ltd’s earnings last quarter?
Epigral Ltd released its earnings results on May 02, 2026. The company reported ₹19 earnings per share for the quarter, beating the consensus estimate of ₹14.3 by ₹4.7.
Is Epigral Ltd overvalued?
According to Wall Street analysts Epigral Ltd’s price is currently Overvalued.
Does Epigral Ltd pay dividends?
Epigral Ltd pays a Semiannually dividend of ₹3.5 which represents an annual dividend yield of 0.46%. See more information on Epigral Ltd dividends here
What is Epigral Ltd’s EPS estimate?
Epigral Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Epigral Ltd have?
Epigral Ltd has 43,141,340 shares outstanding.
What happened to Epigral Ltd’s price movement after its last earnings report?
Epigral Ltd reported an EPS of ₹19 in its last earnings report, beating expectations of ₹14.3. Following the earnings report the stock price went up 0.894%.
Which hedge fund is a major shareholder of Epigral Ltd?
Currently, no hedge funds are holding shares in IN:EPIGRAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Epigral Ltd
Epigral Limited manufactures and sells chlor-alkali and related derivatives in India and internationally. The company offers chlorinated polyvinyl chloride (CPVC) resins, epichlorohydrin, chloromethanes, hydrogen peroxide, caustic soda, chlorine, hydrogen, and caustic potash products. It also trades in agrochemical products. The company serves various sectors, including CPVC pipes and fittings, windmills, construction, paints and coatings, electronics, water treatment, agrochemicals, pharmaceuticals, refineries, soap and detergents, fluoropolymers, paper and pulp, textiles, alumina, polyurethane foam, lithium, and polytetrafluoroethylene (PTFE) pipes. The company was formerly known as Meghmani Finechem Limited and changed its name to Epigral Limited in August 2023. Epigral Limited was incorporated in 2007 and is based in Ahmedabad, India.
Technical Analysis
Gufic Biosciences Limited
―
Marksans Pharma Limited
―
Shilpa Medicare Limited
―
Strides Pharma Science Ltd
―
Supriya Lifescience Limited
―